Skip to main content
padlock icon - secure page this page is secure

In Vitro and In Vivo Evaluation of [99mTc(CO)3]-Radiolabeled ErbB-2-Targeting Peptides for Breast Carcinoma Imaging

Buy Article:

$68.00 + tax (Refund Policy)

ErbB-2 is a type 1 receptor tyrosine kinase over-expressed on ~30% of breast cancers and is an attractive target for the development of new diagnostic and therapeutic agents. In this study, an ErbB-2-targeting peptide, KCCYSL, previously isolated using bacteriophage display, was radiolabeled with [99mTc(H2O)3(CO)3]+ and examined for breast cancer in vitro cell binding and in vivo biodistribution and breast cancer imaging propensities.

KCCYSL peptide was synthesized with the chelates diaminopropionc acid (DAP), Nα-histidinyl acetic acid [(NαHis)Ac], and 4-Ala-1,2-3-Triazol-1-acetic acid [(Ala-Triazol)Ac] at its amino-terminus via a gly-ser-gly (GSG) spacer and radiolabeled with [99mTc(H2O)3(CO)3]+. Radiolabeled peptide binding to cultured human MDA-MB-435 breast carcinoma cells was examined. Biodistribution and single photon emission computed tomography (SPECT)/CT imaging of the radiolabeled peptides were evaluated in female SCID mice bearing human MDA-MB-435 breast tumors.

Results demonstrated that 99mTc(CO)3-DAP-GSG-KCCYSL, 99mTc(CO)3-(NαHis)Ac-GSG-KCCYSL and 99mTc(CO)3- (Ala-Triazol)Ac-GSG-KCCYSL were stable and bound to MDA-MB-435 cells. In vivo biodistribution studies revealed that tumor uptake of 99mTc(CO)3-DAP-GSG-KCCYSL was 1.67 ±0.16, 1.25 ±0.61, 0.88 ±0.12, 0.30 ±0.06 % ID/g at 1, 2, 4, and 24 h post injection, respectively. Tumor uptake of 99mTc(CO)3-(NαHis)Ac-GSG-KCCYSL was 0.76 ±0.13, 0.75 ±0.40, 0.33 ±0.08, 0.16 ±0.02 % ID/g at 1, 2, 4, and 24 h post injection, respectively. Tumor uptake of 99mTc(CO)3-(Ala- Triazol)Ac-GSG-KCCYSL was 1.15 ±0.12, 0.63 ±0.09, 0.30 ±0.02, 0.09 ±0.02 % ID/g at 1, 2, 4, and 24 h post injection, respectively. SPECT/CT studies showed tumor selective uptake of the peptides in the tumor-bearing mice. Specific uptake was confirmed by competitive receptor blocking studies.

99mTc(CO)3-DAP-GSG-KCCYSL and 99mTc(CO)3-(Ala-Triazol)Ac-GSG-KCCYSL may be better as imaging agents due to their higher tumor to non-target uptake ratios than 99mTc(CO)3-(NαHis)Ac-GSG-KCCYSL.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: (SPECT)/CT imaging; Azidoacetic acid; BBN analogues; Breast Carcinoma Imaging; Breast cancer; Cell Culture; Cell Lines; ErbB-2; ErbB-2-Targeting Peptides; Genzyme; HPLC; High Performance Liquid; Laemmli Buffer; Liquid Chromatography-Mass Spectrometry; N-histidinyl acetic acid [(NHis)Ac]; Novabiochem; Peptide Synthesis; Technetium-99m; Thin Layer Chromatography; [99mTc(CO)]-Radiolabeled; a gly-ser-gly (GSG); chelates diaminopropionc acid (DAP); click chemistry; diaminopropionc acid; epidermal growth factor receptor; human breast carcinoma cells; murine monoclonal antibody; peptide; pertuzumab; phenol; phosphate-buffered solution; phosphatidylinositol 3-kinase; preparative HPLC; radioimaging; single photon computed emission tomography; technetium; thioanisole; trastuzumab; tricarbonyl; trifluoroacetic acid; type 1 receptor tyrosine kinase

Document Type: Research Article

Publication date: October 1, 2010

More about this publication?
  • Current Radiopharmaceuticals publishes original research articles, letters, reviews, drug clinical trial studies and guest edited issues on all aspects of research and development of radiolabelled compound preparations. The scope of the journal covers the following areas: radio imaging techniques, therapies; preparation and application of radionuclide compounds including the incorporation of tracer methods used in scientific research and applications.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more